Skip to main content

Armata Pharmaceuticals, Inc. (ARMP) Stock Forecast

Data as of May 10, 2026

Healthcare · Current price $8.39 (-8.25%)

Consensus Target
$15.00
Upside
+78.7%
Analysts
1
Rating
Buy(2.00)

Price Target Range

Low $15.00High $15.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

ARMP vs Sector & Market

MetricARMPHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count1819
Target Upside+78.7%+1710.9%+16.4%
P/E Ratio-2.043.3027.60

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$1M$1M$1M1
2026-09-30$1M$1M$1M1
2026-12-31$1M$1M$1M1
2027-12-31$6M$6M$6M1
2028-12-31$56M$56M$56M1
2029-12-31$19M$19M$19M1
2030-12-31$57M$57M$57M1

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$-0.39$-0.39$-0.391
2026-09-30$-0.23$-0.23$-0.231
2026-12-31$-0.25$-0.25$-0.251
2027-12-31$-0.93$-0.93$-0.931
2028-12-31$-0.95$-0.95$-0.951
2029-12-31$-0.56$-0.56$-0.561
2030-12-31$-0.10$-0.10$-0.101

Frequently Asked Questions

What is the analyst consensus for ARMP?

The consensus among 1 analysts covering Armata Pharmaceuticals, Inc. (ARMP) is Buy with an average price target of $15.00.

What is the highest price target for ARMP?

The highest analyst price target for ARMP is $15.00.

What is the lowest price target for ARMP?

The lowest analyst price target for ARMP is $15.00.

How many analysts cover ARMP?

1 analysts have issued ratings for Armata Pharmaceuticals, Inc. in the past 12 months.

Is ARMP a buy or sell right now?

Based on 1 analyst ratings, ARMP has a consensus rating of Buy (2.00/5) with a +78.7% upside to the consensus target of $15.00.

What are the earnings estimates for ARMP?

Analysts estimate ARMP will report EPS of $-0.39 for the period ending 2026-06-30, with revenue estimated at $1M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.